Can novel regulatory and clinical requirements reshape early-stage financing?

Regulatory, clinical and reimbursement requirements seem to influence what “de-risked” now means for investors. For early-stage MedTech, diagnostics and digital health companies, evidence expectations directly impact the ability to close funding rounds. To what extent are novel validation approaches influencing financing dynamics? Are these evolving requirements slowing innovation or creating clearer pathways? Speakers will discuss new frameworks and the impact on early-stage financing.